Holen Sie sich die Stockscreener-App
39.03
3.83%
1.44
Vorhandelsmarkt:
39.00
-0.03
-0.08%
Schlusskurs vom Vortag:
$37.59
Offen:
$38.65
24-Stunden-Volumen:
758.37K
Relative Volume:
0.83
Marktkapitalisierung:
$3.95B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-804.34M
KGV:
-4.1477
EPS:
-9.41
Netto-Cashflow:
$-531.06M
1W Leistung:
+9.73%
1M Leistung:
+7.64%
6M Leistung:
+8.48%
1J Leistung:
-12.00%
1-Tages-Spanne:
$37.75
$39.36
1-Wochen-Bereich:
$35.01
$39.36
52-Wochen-Spanne:
$26.80
$62.21
Biohaven Ltd Stock (BHVN) Company Profile
Firmenname
Biohaven Ltd
Sektor
Branche
Telefon
203-404-0410
Adresse
215 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie BHVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
39.03 | 3.95B | 0 | -804.34M | -531.06M | -9.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-16 | Eingeleitet | Jefferies | Buy |
| 2024-09-04 | Eingeleitet | Bernstein | Outperform |
| 2024-07-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2023-12-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-01-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-04 | Eingeleitet | JP Morgan | Overweight |
| 2022-12-02 | Eingeleitet | BTIG Research | Buy |
| 2022-10-26 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-05-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Herabstufung | UBS | Buy → Neutral |
| 2021-08-03 | Bestätigt | Canaccord Genuity | Buy |
| 2021-03-11 | Eingeleitet | UBS | Buy |
| 2020-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-17 | Eingeleitet | Cowen | Outperform |
| 2020-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Outperform |
| 2019-06-25 | Bestätigt | Canaccord Genuity | Buy |
| 2019-05-06 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Bestätigt | Needham | Buy |
| 2018-07-03 | Bestätigt | Needham | Buy |
| 2018-07-02 | Bestätigt | Needham | Buy |
| 2018-04-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Bestätigt | Canaccord Genuity | Buy |
| 2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-03 | Bestätigt | Needham | Buy |
Alle ansehen
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
Biohaven Ltd. (NYSE:BHVN) Stock Holdings Raised by ARS Investment Partners LLC - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Given Average Rating of "Buy" by Brokerages - MarketBeat
Insider Stock Buying Reaches US$23.8m On Biohaven - Simply Wall St
Biohaven’s stock surges as treatment slows progress of neurological disorder - MSN
Biohaven (NYSE:BHVN) Trading Down 6.4%Here's What Happened - MarketBeat
Biohaven Refines Epilepsy Trial Design With Patient-Centric Focus - Clinical Leader
Motor Neuron Disease Clinical and Non-Clinical Studies, Key - openPR
Deal Watch: Bausch Companies Set Hectic Pace At J.P. Morgan With Five Deals - News & Insights
Biohaven (NYSE:BHVN) Stock Price Down 6.4%Should You Sell? - MarketBeat
Why Biohaven Ltd. Stocks Are Rising Now - TipRanks
What's Going On With Merus Stock Monday?Biohaven (NYSE:BHVN), Merus (NASDAQ:MRUS) - Benzinga
Biohaven & Merus Team Up to Develop Novel Bispecific ADC Therapies - Contract Pharma
Biohaven Showcases TRAP Degraders at J.P. Morgan Conference - TipRanks
Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generatio - PR Newswire
Merus and Biohaven Partner to Develop Next-Generation Cancer-Fighting ADC Therapies - StockTitan
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs - The Manila Times
Biohaven (NYSE:BHVN) Shares Gap DownHere's What Happened - MarketBeat
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire
JPMorgan Chase & Co. Increases Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Insider Buying: Biohaven Independent Director Bought US$1.0m Of Shares - Yahoo Finance
Long Term Trading Analysis for (BHVN) - Stock Traders Daily
Biohaven Announces Conference Call to Discuss Topline Pivotal St - GuruFocus.com
Biohaven Stock Surges After Director Acquires Shares Worth Over $1M: Retail Sentiment Turns Bullish - MSN
Biohaven (NYSE:BHVN) Shares Gap Up on Insider Buying Activity - MarketBeat
John W. Childs Buys 29,000 Shares of Biohaven Ltd. (NYSE:BHVN) Stock - MarketBeat
Biohaven Ltd. Stocks Surge Amid Positive Developments - TipRanks
Biohaven director John Childs acquires shares worth $1.04 million By Investing.com - Investing.com Nigeria
Biohaven director John Childs acquires shares worth $1.04 million - Investing.com
Biohaven Ltd. (NYSE:BHVN) Receives $63.00 Average Price Target from Brokerages - MarketBeat
Biohaven Enters Oversold Territory (BHVN) - Nasdaq
How To Trade (BHVN) - Stock Traders Daily
Geode Capital Management LLC Purchases 44,174 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Bernstein reiterates Outperform rating on Biohaven stock, sees strong upside potential By Investing.com - Investing.com South Africa
Biohaven (NYSE:BHVN) Stock Price Down 6.1%What's Next? - MarketBeat
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval - AOL
Bernstein reiterates Outperform rating on Biohaven stock, sees strong upside potential - Investing.com Australia
Biohaven's (BHVN) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Biohaven (NYSE:BHVN) Given Buy Rating at HC Wainwright - MarketBeat
Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
Biohaven Pharma (BHVN) Reports Positive Phase 1 Degrader Data - StreetInsider.com
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - PR Newswire
Biohaven Ltd. (NYSE:BHVN) Holdings Boosted by Barclays PLC - MarketBeat
Wellington Management Group LLP Boosts Stock Holdings in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven's SWOT analysis: neurological drug developer's stock poised for growth - Investing.com
12 Best Weight Loss Stocks to Buy According to Hedge Funds - Insider Monkey
State Street Corp Sells 393,278 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Announces Proposed Public Offering of Common Shares - The Eastern Progress Online
Finanzdaten der Biohaven Ltd-Aktie (BHVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):